1. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients
- Author
-
Isabel Vera, Esther Garcia-Planella, M Sierra, Noemí Manceñido, Ramón Pajares-Villarroya, Saoia Rubio, Natalia García-Morales, Noelia Cano-Sanz, Marta Maia Bosca-Watts, Cristina Alba, David Martí-Aguado, B. Beltrán, María Pilar Ballester, Antonio Cañada, Marisa Iborra, Carlos Taxonera, Pilar Nos, Marta Calvo, Óscar Nantes Castillejo, Federico Bertoletti, and Elena Cerrillo
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Anti-Inflammatory Agents ,lcsh:Medicine ,Article ,Inflammatory bowel disease ,Medication Adherence ,Persistence (computer science) ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,lcsh:Science ,Adverse effect ,Colectomy ,030203 arthritis & rheumatology ,Multidisciplinary ,Tumor Necrosis Factor-alpha ,business.industry ,lcsh:R ,Antibodies, Monoclonal ,Middle Aged ,medicine.disease ,Ulcerative colitis ,Golimumab ,Clinical trial ,Crohn's disease ,Safety profile ,Treatment Outcome ,Spain ,Colitis, Ulcerative ,Female ,lcsh:Q ,030211 gastroenterology & hepatology ,Observational study ,business ,Follow-Up Studies ,medicine.drug - Abstract
Golimumab has demonstrated its long-term efficacy and safety in ulcerative colitis in clinical trials, but no data of long-term persistence has been published from real world. To estimate long-term persistence of golimumab, as well as factors associated with longer persistence, in patients with ulcerative colitis in real life. Observational multicentre study including adult patients with ulcerative colitis treated with golimumab and with at least twelve months of follow-up. We included 190 patients, 105 (55.26%) naive to anti-TNF, with mean disease duration of 9.32 ± 8.09 years. Probability of persistence was 63%, 46%, 39% and 27% at 1, 2, 3 and 4 years, respectively. Persistence was lower in patients with primary failure to previous anti-TNF. Eighty-two (43.16%) patients needed dose intensification during follow-up, with a mean time until intensification of 8.03 ± 8.64 months. Dose intensification and lower disease duration predicted higher persistence with golimumab (p = 0.037 and p = 0.008, respectively). During a follow-up of 17.25 ± 15.83 months, 32 (16.5%) patients needed hospitalisation and 11 (6%) underwent colectomy. No unexpected adverse events were reported. Golimumab has demonstrated good persistence and safety profile for long treatment in ulcerative colitis patients.
- Published
- 2020